{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:42:50Z","timestamp":1790772170020,"version":"4.1.0"},"reference-count":24,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T00:00:00Z","timestamp":1698624000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Etranacogene dezaparvovec gene therapy for haemophilia B demonstrated superior efficacy at 24 months in reducing bleeds versus a \u22656\u2010month lead\u2010in period of prophylaxis with FIX products in the phase 3 trial, HOPE\u2010B. In the absence of head\u2010to\u2010head comparisons of etranacogene dezaparvovec versus FIX products, indirect treatment comparisons (ITC) can be used.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To compare the efficacy of etranacogene dezaparvovec versus rIX\u2010FP, rFIXFc and N9\u2010GP using ITC, and support HOPE\u2010B results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data were leveraged from Phase 3 pivotal trials: HOPE\u2010B, PROLONG\u20109FP, B\u2010LONG and Paradigm 2. Annualised bleeding rates (ABR), spontaneous (AsBR) and joint (AjBR) bleeding rates, percentage of patients with no bleeds, and FIX consumption were assessed using inverse probability of treatment weighting and matching adjusted indirect comparisons.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Etranacogene dezaparvovec demonstrated statistically significantly lower bleeding rates versus all comparators. Rate ratios for ABR, AsBR and AjBR versus rIX\u2010FP were 0.19 (<jats:italic>p<\/jats:italic>\u00a0&lt;\u00a0.0001), 0.08 (<jats:italic>p<\/jats:italic>\u00a0&lt;\u00a0.0001) and 0.09 (<jats:italic>p<\/jats:italic>\u00a0&lt;\u00a0.0001), respectively. Rate ratios for ABR, AsBR and AjBR versus rFIXFc were 0.14 (<jats:italic>p<\/jats:italic>\u00a0&lt;\u00a0.0001), 0.13 (<jats:italic>p<\/jats:italic>\u00a0=\u00a0.0083) and 0.15 (<jats:italic>p<\/jats:italic>\u00a0=\u00a0.0111), respectively. Rate ratios for ABR and AsBR, versus N9\u2010GP were 0.24 (<jats:italic>p<\/jats:italic>\u00a0=\u00a0.0231) and 0.13 (<jats:italic>p<\/jats:italic>\u00a0=\u00a0.0071), respectively. Etranacogene dezaparvovec demonstrated significantly higher percentage of patients with no bleeds versus rIX\u2010FP and rFIXFc; odds ratios: 17.60 (<jats:italic>p<\/jats:italic>\u00a0&lt;\u00a0.0001) and 5.65 (<jats:italic>p<\/jats:italic>\u00a0=\u00a0.0037), respectively. Etranacogene dezaparvovec resulted in significantly lower FIX consumption than all comparators.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>ITC suggests that etranacogene dezaparvovec offers patients with haemophilia B (\u22642% of normal FIX expression) a single dose treatment that can significantly reduce bleeding rates and eliminate routine infusions associated with FIX therapies.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hae.14882","type":"journal-article","created":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T15:20:12Z","timestamp":1698679212000},"page":"75-86","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec versus extended half\u2010life factor IX therapies for severe or moderately severe haemophilia B"],"prefix":"10.1111","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4194-8183","authenticated-orcid":false,"given":"Robert","family":"Klamroth","sequence":"first","affiliation":[{"name":"Department for Internal Medicine Haemophilia Treatment Centre Vivantes Klinikum im Friedrichshain  Berlin Germany"},{"name":"Institute of Experimental Hematology and Transfusion Medicine University Hospital Bonn, Medical Faculty, University of Bonn Bonn Nordrhein\u2010Westfalen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Bonner","sequence":"additional","affiliation":[{"name":"EVERSANA  Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Gomez","sequence":"additional","affiliation":[{"name":"Haemophilia Centre and Thrombosis Unit Royal Free London NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E.","family":"Monahan","sequence":"additional","affiliation":[{"name":"CSL Behring  King of Prussia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirk","family":"Szafranski","sequence":"additional","affiliation":[{"name":"EVERSANA  Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zhang","sequence":"additional","affiliation":[{"name":"CSL Behring  King of Prussia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Walsh","sequence":"additional","affiliation":[{"name":"EVERSANA  Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Wang","sequence":"additional","affiliation":[{"name":"EVERSANA  Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1677-3839","authenticated-orcid":false,"given":"Songkai","family":"Yan","sequence":"additional","affiliation":[{"name":"CSL Behring  King of Prussia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,10,30]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"Clinical Trial Protocol: Phase III open\u2010label single\u2010dose multi\u2010center multinational trial investigating a serotype 5 adeno\u2010associated viral vector containing the Padua variant of a codon\u2010optimized human factor IX gene (AAV5\u2010hFIXcoPadua AMT\u2010061) administered to adult subjects with severe or moderately severe hemophilia B.2022."},{"key":"e_1_2_10_3_1","unstructured":"Adivo.Patient Prophylactic Market Share for all Factor IX Drugs in U.S. and EU5 from 3Q 2020 Adivo Source.2021."},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S139851"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211644"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000811"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305074"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-573055"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-09-669234"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2019.1620246"},{"key":"e_1_2_10_11_1","unstructured":"PhillippoDM AdesAE DiasS PalmerS AbramsKR WeltonNJ.NICE DSU Technical Support Document 18: Methods for population\u2010adjusted indirect comparisons in submission to NICE.2016."},{"key":"e_1_2_10_12_1","unstructured":"HEMGENIX [package insert].CSL Behring;2023.https:\/\/www.fda.gov\/media\/163467\/download?attachment"},{"key":"e_1_2_10_13_1","unstructured":"Annex I: Summary of product characteristics for Hemgenix.European Medicines Agency;2023.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/hemgenix\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/00273171.2011.568786"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6607"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.05.004"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1198\/000313004X5824"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1177\/0962280215584401"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/pan\/mpr025"},{"key":"e_1_2_10_20_1","unstructured":"R: A language and environment for statistical computing. Accessed March 24 2022.https:\/\/www.R\u2010project.org\/"},{"key":"e_1_2_10_21_1","unstructured":"Greifer N. WeightIt:Weighting for Covariate Balance in Observational Studies. R package version 0.12.0. Accessed March 24 2022.https:\/\/CRAN.R\u2010project.org\/package=WeightIt"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X17725740"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S312885"},{"key":"e_1_2_10_24_1","unstructured":"IDELVION [package insert].CSL Behring; 2021.https:\/\/www.fda.gov\/media\/96526\/download?attachment"},{"key":"e_1_2_10_25_1","unstructured":"Annex I: Summary of product characteristics for Idelvion.European Medicines Agency;2021.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/idelvion\u2010epar\u2010product\u2010information_en.pdf"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.14882","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T13:09:37Z","timestamp":1712322577000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.14882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,30]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1111\/hae.14882"],"URL":"https:\/\/doi.org\/10.1111\/hae.14882","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,30]]},"assertion":[{"value":"2023-05-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}